ClinicalTrials.gg
WithdrawnNCT03255330GabaNeuBolUpdated Mar 7, 2019

The Effect of Gabapentin Used as a Preemptive to the Emergence and Development Chronic Neuropathic Pain in Patients After Spinal Cord Trauma

A Phase 3 interventional study of Gabapentin and Metamizol in Chronic Pain Due to Trauma and Spinal Cord Injuries, sponsored by Masaryk University. Withdrawn at 1 site in Czechia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-03-07.

Sponsored by Masaryk University · Phase 3, Interventional, and Treatment

Why this study was withdrawn
no participant enrolled

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Spinal Cord Injuries with a site in Czechia — 2 open to participants now, 3 under way, none of them phase 3. Spinal Cord Injuries · Czechia.

Started
2017
the only one that year
Phase 3
2 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Masaryk University

Among the 10 studies in Spinal Cord Injuries with a site in Czechia, this one is the only one that started in 2017, is one of 2 in phase 3, and was the 3rd registered.

Spinal Cord Injuries

2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

2 of the 10 studies in Spinal Cord Injuries with a site in Czechia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Spinal Cord Injuries with a site in Czechia, or all of them as a file.
02

Study summary

Study of the effect of gabapentin used as a preemptive to the emergence and development chronic neuropathic pain in patients after spinal cord trauma

03

Conditions studied

  • Chronic Pain Due to Trauma
  • Spinal Cord Injuries
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women, age 18 - 65 years
  2. Signed written
  3. Patients after complete/non-complete spinal lesion, after surgery
  4. Patients with spinal cord trauma caused mechanically demanding (due a injury of a bone fragment, a disk, a translation spinal canal)
  5. Patient willing and able to comply with the study protocol
  6. Male and females with a highly effective method of plus an additional barrier method

Exclusion criteria

Exclusion Criteria:

  1. Patients with spinal cord lesion ischemic etiology
  2. Pregnant women, nursing or childbearing age with a positive pregnancy test input
  3. Patients unable or unwilling to comply with the study protocol
  4. Acute pancreatitis in 1 year from the start of the study
  5. Chronic pancreatitis in the case history
  6. Active or uncontrolled infectious diseases
  7. to any component of the product
  8. Active disease
  9. Serious neurological disease with the incidence chronic neuropathic pain
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm G1800

    administration of gabapentin with a gradual increasing dose of up to 1800 mg / day

    Drug: Gabapentin

  • Active comparator
    G0

    Standardized medical treatment of central neuropathic pain: metamizole, tramadol

    Drug: Metamizol · Drug: Tramadol

Interventions

  • Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present

    Also known as: Gabapentinum

  • Standardized treatment

  • Standardized treatment

06

What researchers measure

Primary outcomes

  1. Assessment the analgesic effect of gabapentin

    The decrease of the incidence of chronic neuropathic pain in 3 months after initiation of the gabapentin treatment in 3 months after initiation of the gabapentin treatment

    Time frame: in 3 months after initiation of the gabapentin treatment

Secondary outcomes

  1. The decrease of the incidence of chronic neuropathic pain

    The decrease of the incidence of chronic neuropathic pain in 6., 9. and 12. months after initiation of the gabapentin treatment

    Time frame: in 6., 9. and 12. months after initiation of the gabapentin treatment

  2. The number of painful episodes

    The number of painful episodes requiring treatment of rescue medication (in 3., 6., 9. and 12. months after initiation of the gabapentin treatment)

    Time frame: in 3., 6., 9. and 12. months after initiation of the gabapentin treatment

  3. The decrease of the consumption of rescue medication

    The decrease of the consumption of rescue medication in 3., 6., 9. and 12. months after initiation of the gabapentin treatment

    Time frame: in 3., 6., 9. and 12. months after initiation of the gabapentin treatment

  4. Absolute and percentage change in average pain

    Absolute and percentage change in average pain after initiation of therapy with gabapentin (baseline) in 3., 6., 9. and 12. months

    Time frame: in 3., 6., 9. and 12. months

  5. Quality of life

    Quality of life, assessment of neurological pain and psychological state measured by questionnaires PainDETECT, SQUALA and SCL-R

    Time frame: in week 1, 3., 6., 9. and 12. months after initiation of the gabapentin treatment

07

Study locations

1 site
  • Fakultní nemocnice Brno
    Brno, Czechia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2017; primary completion for Feb 2020, 28 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2017
First posted
Aug 21, 2017
StartEst.
Oct 2017
Primary completionEst.
Feb 2020
CompletionEst.
Aug 2020
Last update
Mar 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03255330
Lead sponsor
Masaryk University
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Oct 2017 (estimated)
Primary completion
Feb 2020 (estimated)
Completion
Aug 2020 (estimated)
Last update
Mar 7, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion